Greater Cannabis Company, Inc. Annual Report: A Year in Review

I’ve put together this plain-English guide to help you understand how Greater Cannabis Company, Inc. performed this year. My goal is to turn complex financial filings into clear information to help you decide if this company fits your investment goals.

1. What does this company do?

Greater Cannabis Company is an early-stage biotech firm developing cannabinoid-based medicines. Unlike retail cannabis brands, they don’t run dispensaries or sell consumer products. Instead, they hold an exclusive global license from the Hebrew University of Jerusalem for a unique cannabinoid formula. They aim to treat neurodegenerative and neurodevelopmental conditions, specifically autism, Parkinson’s, and Alzheimer’s. As a clinical-stage developer, their main goal is to navigate the regulatory process to win FDA approval for their drug candidates.

2. Financial performance: The "Building" Phase

The company is currently pre-revenue, meaning they made zero money from product sales this year. Most of their spending went toward administrative costs and legal fees to protect their intellectual property. They are currently in a "holding pattern" regarding their main goal: starting Phase 2 clinical trials. This delay stems from an inability to secure a steady supply of the pharmaceutical-grade ingredients required for testing. With cash reserves often dipping below $100,000, the company lacks the millions needed to fund these human trials.

3. Major changes and "The Big Split"

In October 2025, the company executed a 1-for-1,500 reverse stock split. They did this to stop being classified as a "penny stock," which often struggles with low trading volume and the risk of being kicked off major exchanges. By reducing the total number of shares by 1,500, they mathematically boosted the price per share to meet listing requirements. While this doesn't change the company’s total market value, it acts as a defensive move to stay compliant and potentially attract larger institutional investors who often avoid stocks priced below $1.00.

4. Financial health and risks

The company’s financial health is very shaky, and auditors have issued a "going concern" warning, which means they may not be able to stay in business.

• The Funding Gap: The company is running out of cash. They need millions in new funding to move from research to clinical trials. Without a new stock sale or a strategic partner, they may not have enough money to keep the lights on.
• Dilution: The company carries debt that lenders can convert into shares at a discount. This creates a cycle where the company issues more shares to pay off debt, which reduces your ownership percentage in the company.
• Uncertainty: Success depends on outside factors. They rely on third-party suppliers for ingredients, and clinical trials are notoriously difficult. Even with funding, there is no guarantee their drugs will be safe or effective.

5. Is this a good investment?

This is a high-risk, speculative investment. The company has no history of sales and relies entirely on outside funding to survive. Their business model is "all or nothing": it depends on sourcing ingredients, passing expensive trials, and winning regulatory approval.

If you want a stable company with steady profits, look elsewhere. This is a "bet on the science" company with the highest possible risk profile. You should be prepared for the possibility of losing your entire investment, as the company’s survival depends on raising capital despite having no commercial products.

Final Thought for Investors: Before moving forward, ask yourself if you are comfortable with a "binary" outcome—where the company either succeeds in bringing a drug to market or potentially runs out of cash entirely. If you are looking for a safer, more predictable investment, this company likely does not align with your strategy.